PYGO2 and prostate cancer: PYGO2 upregulation is associated with higher Gleason score and metastasis to lymph nodes and bone, and PYGO2 overexpression increased in vivo tumor growth and lymph node invasion of immortalized LHMK prostate cancer cells (derived from primary prostate cells transformed with SV40 Large T, hTERT, Myc and PI3K) while PYGO2 shRNA-mediated depletion reduced primary tumor burden and metastasis in the PC-3 xenograft model [96].